Healthcare
Zelira Therapeutics Limited(ZLDAF)
Live Price
Offline$0.35
+0.00% today
1Y Change
+25.36%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $10.00M
- Revenue Growth
- -99.3%
- EPS Growth
- +90.1%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Zelira Therapeutics Limited (ZLDAF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.35 and up 25.4% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -99.3%, EPS growth of +90.1%, a dividend yield of 0.0%. What stands out right now is revenue -99.3%, EPS +90.1%, free cash flow -11.8% with operating margin -663833.7% and ROIC 202.3%. Valuation already assumes a fairly strong business story at price/sales 9081.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ZLDAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-99.3% vs +7.6% peer median
Operating Margin
Below sector median
-663833.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 24, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -99.3% and EPS is at +90.1%, with operating margin around -663833.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 24, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Sep 1, 2025 | โ | +0.0% | +0.0% | +16.1% |
2025 Feb 26, 2025 | โ | +0.0% | +0.0% | -3.2% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ZLDAF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
ZLDAF Max Drawdown
-33.16%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ZLDAF and SPY.
Company Overview
Zelira Therapeutics Limited
Other OTC
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
- Leadership
- Oludare Odumosu
- IPO Date
- Mar 7, 2017
- Employees
- 8
- Street Address
- 101 St George's Terrace
- Mailing
- Perth, WA, 6000
- Region
- Perth, WA, AU
- Reporting Currency
- USD
- Investor Line
- 61 8 6558 0886
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 9081.8
- Price/Book
- โ
Growth
- Revenue
- -99.3%
- EPS
- +90.1%
- Free Cash Flow
- -11.8%
Profitability
- Gross Margin
- -122587.0%
- Operating Margin
- -663833.7%
- Net Margin
- -553873.6%
- ROE
- 56.4%
- ROIC
- 202.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.11
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.